Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Tramadol, zopiclone and zaleplon reclassified as controlled drugs

The common painkiller has been placed in schedule 3 while the hypnotics become schedule 4 part 1

Tramadol has become a controlled drug along with zopiclone and zaleplon following regulations that came into effect yesterday (June 10).


The painkiller has been placed in schedule 3 and reclassified as a class C drug.


The Home Office announced the change in March, following a 12-week consultation carried out last summer in response to a surge in deaths involving tramadol.


More clinical news Life-saving statins should stay, rules MHRA

Vasodilator available for PAH patients

End 'complacency' in asthma treatment, warns medical college


Tramadol remains exempt from the safe custody requirements of other schedule 3 drugs, as a result of responses to the consultation, but is subject to full prescription writing requirements.


Zopiclone and zaleplon have been placed alongside zolpidem and benzodiazepines in schedule 4 part 1 class.


Alongside the changes, the government confirmed that the ADHD drug lisdexamphetamine remains in schedule 2.

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD017059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel